RLMD Relmada Therapeutics Inc

Price (delayed)

$6.34

Market cap

$665M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$655.23M

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed ...

Highlights
RLMD's equity has soared by 153% from the previous quarter
The EPS has soared by 56% YoY and by 23% from the previous quarter
Relmada Therapeutics's net income has increased by 22% YoY but it has decreased by 2.6% QoQ

Key stats

What are the main financial stats of RLMD

RLMD stock price

How has the Relmada Therapeutics stock price performed over time
Intraday
0.16%
1 week
-12.55%
1 month
-14.44%
1 year
759.2%
YTD
31.26%
QTD
-8.91%

Financial performance

How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.34M
Net income
-$58.88M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's operating income has increased by 24% YoY but it has decreased by 2.1% from the previous quarter
Relmada Therapeutics's net income has increased by 22% YoY but it has decreased by 2.6% QoQ

Price vs fundamentals

How does RLMD's price correlate with its fundamentals

Growth

What is Relmada Therapeutics's growth rate over time

Valuation

What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
3.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 56% YoY and by 23% from the previous quarter
RLMD's equity has soared by 153% from the previous quarter
The P/B is 22% less than the last 4 quarters average of 3.9 but 13% more than the 5-year quarterly average of 2.7

Efficiency

How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has surged by 61% YoY and by 58% QoQ
RLMD's return on invested capital has surged by 61% year-on-year and by 59% since the previous quarter
The ROA has soared by 57% year-on-year and by 56% since the previous quarter

Dividends

What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLMD.

Financial health

How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has surged by 150% QoQ
RLMD's total liabilities has soared by 122% QoQ
RLMD's debt is 100% smaller than its equity
RLMD's equity has soared by 153% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.